Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for... Hindawi Sarcoma Volume 2019, Article ID 7608743, 1 page https://doi.org/10.1155/2019/7608743 Corrigendum Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy” 1 2 3 4 5 Edwin Choy , Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh , 6 7 8 9 10 Suzanne George, Scott Okuno , Raphael Pollock, Rajiv M. Patel, Antje Hoering, and Shreyaskumar Patel Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA 2e Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 250 Lincoln Tower, Columbus, OH 43210, USA Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, New York, NY 10065, USA University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Rm C-407 MIB/SPC 5843, Ann Arbor, MI 48109, USA Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, 450 Brookline Ave, D-1212, Brookline, MA 02215, USA Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA Ohio State University Wexner Medical Center, 410 West 10th Avenue, N924 Doan Hall, Columbus, OH 43206, USA Michigan Medicine, Department of Pathology, 1301 Catherine Street, SPC 5602, 3261G Medical Science I, Ann Arbor, MI 48109-5602, USA Cancer Research and Biostatistics, 1730 Minor Ave, Suite 1900, Seattle, WA 98101, USA MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA Correspondence should be addressed to Edwin Choy; echoy@mgh.harvard.edu Received 10 July 2019; Accepted 15 July 2019; Published 27 August 2019 Copyright © 2019 Edwin Choy et al. #is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the article titled “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Re- lapse following Prior Treatment with Gemcitabine-Con- taining #erapy” [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner. References [1] E. Choy, K. Ballman, J. Chen et al., “SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy,” Sarcoma, vol. 2018, Article ID 2068517, 9 pages, 2018. MEDIATORS of INFLAMMATION The Scientific Gastroenterology Journal of World Journal Research and Practice Diabetes Research Disease Markers Hindawi Hindawi Publishing Corporation Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 http://www www.hindawi.com .hindawi.com V Volume 2018 olume 2013 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 International Journal of Journal of Immunology Research Endocrinology Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Submit your manuscripts at www.hindawi.com BioMed PPAR Research Research International Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Journal of Obesity Evidence-Based Journal of Journal of Stem Cells Complementary and Ophthalmology International Alternative Medicine Oncology Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2013 Parkinson’s Disease Computational and Behavioural Mathematical Methods AIDS Oxidative Medicine and in Medicine Neurology Research and Treatment Cellular Longevity Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Sarcoma Hindawi Publishing Corporation

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”

Loading next page...
 
/lp/hindawi-publishing-corporation/corrigendum-to-sarc018-spore02-phase-ii-study-of-mocetinostat-0rE34VnJLX

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Hindawi Publishing Corporation
Copyright
Copyright © 2019 Edwin Choy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN
1357-714X
eISSN
1369-1643
DOI
10.1155/2019/7608743
Publisher site
See Article on Publisher Site

Abstract

Hindawi Sarcoma Volume 2019, Article ID 7608743, 1 page https://doi.org/10.1155/2019/7608743 Corrigendum Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy” 1 2 3 4 5 Edwin Choy , Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh , 6 7 8 9 10 Suzanne George, Scott Okuno , Raphael Pollock, Rajiv M. Patel, Antje Hoering, and Shreyaskumar Patel Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA 2e Ohio State University Comprehensive Cancer Center, 1800 Cannon Drive, 250 Lincoln Tower, Columbus, OH 43210, USA Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E. 66th Street, New York, NY 10065, USA University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Rm C-407 MIB/SPC 5843, Ann Arbor, MI 48109, USA Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, 450 Brookline Ave, D-1212, Brookline, MA 02215, USA Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA Ohio State University Wexner Medical Center, 410 West 10th Avenue, N924 Doan Hall, Columbus, OH 43206, USA Michigan Medicine, Department of Pathology, 1301 Catherine Street, SPC 5602, 3261G Medical Science I, Ann Arbor, MI 48109-5602, USA Cancer Research and Biostatistics, 1730 Minor Ave, Suite 1900, Seattle, WA 98101, USA MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA Correspondence should be addressed to Edwin Choy; echoy@mgh.harvard.edu Received 10 July 2019; Accepted 15 July 2019; Published 27 August 2019 Copyright © 2019 Edwin Choy et al. #is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the article titled “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Re- lapse following Prior Treatment with Gemcitabine-Con- taining #erapy” [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner. References [1] E. Choy, K. Ballman, J. Chen et al., “SARC018_SPORE02: phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy,” Sarcoma, vol. 2018, Article ID 2068517, 9 pages, 2018. MEDIATORS of INFLAMMATION The Scientific Gastroenterology Journal of World Journal Research and Practice Diabetes Research Disease Markers Hindawi Hindawi Publishing Corporation Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 http://www www.hindawi.com .hindawi.com V Volume 2018 olume 2013 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 International Journal of Journal of Immunology Research Endocrinology Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Submit your manuscripts at www.hindawi.com BioMed PPAR Research Research International Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 Journal of Obesity Evidence-Based Journal of Journal of Stem Cells Complementary and Ophthalmology International Alternative Medicine Oncology Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2013 Parkinson’s Disease Computational and Behavioural Mathematical Methods AIDS Oxidative Medicine and in Medicine Neurology Research and Treatment Cellular Longevity Hindawi Hindawi Hindawi Hindawi Hindawi www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018 www.hindawi.com Volume 2018

Journal

SarcomaHindawi Publishing Corporation

Published: Aug 27, 2019

References